3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Thromboembolism
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Sorafenib
46
lenvatinib
44
apatinib
23
sintilimab
22
Fluorouracil
21
camrelizumab
20
Oxaliplatin
17
Radiofrequency Ablation
16
Radiosurgery
15
Hepatectomy
15
tislelizumab
14
Leucovorin
14
Radiotherapy
12
Doxorubicin
12
toripalimab
11
Folfox protocol
10
Bevacizumab
10
Immune Checkpoint Inhibitors
9
Epirubicin
9
regorafenib
8
Ethiodized Oil
8
durvalumab
7
donafenib
7
anlotinib
7
Neoadjuvant Therapy
7
pembrolizumab
6
entecavir
6
Surgical Procedures, Operative
6
Nivolumab
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Hepatocellular
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled